1. Operating revenues stood at ₹367 Cr registering growth of 24% YoY
2. EBITDA grew by 21% YoY to ₹98 Cr with margins at 27%
3. 58% of revenue contribution from high value business and rest 42% from legacy business
4. Growth momentum of 10% YoY in high value business and 50% in legacy businesses
5. As per customers, the overall demand was slow due to inventory pile up, with revival in demand the existing inventory is now consumed and order for new inventory will soon be in pipeline from H2
6. Inorganic and refrigerant gas business were able to pass on the incremental prices but the cost were absorbed in specialty segment
R22 prices will further move up and might have impact on next quarter volumes
7. Growth in domestic region will be driven from inorganic business
8. Not to be an API player but considering it as an option to service the customers
9. Short - mid term drivers will be more in agrochemicals industry
10. Mid-long term targets focus on pharma business driven by CRAMS opportunities
Working on new opportunities in inorganic business
Segmental review
Specialty Chemicals
1. Specialty chemicals contributed 41% of revenues in Q3FY22 with 24% growth YoY
2. 51% of revenues from international business in 9MFY22
3. One dedicated plant for specialty chemical molecule with capacity utilisation at 75%
4. Extremely strong pipeline in specialty business mostly coming from agrochemicals and non-pharma non-agro
CRAMS
1. 16.3% revenue contribution in Q3FY22 with shrink in growth of (-15%) YoY
2. All the revenues for CRAMS were from international business in the period of 9MFY22
3. Shift of some of the orders from Q3 to Q4FY22
4. Debottlenecking of CGMP3 approved on the back of robust opportunity pipeline
Inorganic Fluorides
1. 22% of revenue contribution in Q3FY22 with 47% growth YoY
2. 91% of of inorganic fluid sales was in domestic markets and rest 9% in international markets for the period of 9MFY22
3. Increase in realisations helped drive growth
Good traction seen from end user segments especially in India
Refrigerant Business
1. 20% of revenue contribution in Q3FY22 with 54% growth YoY
2. 61% of of inorganic fluid sales was in domestic markets and rest 39% in international markets for the period of 9MFY22
3. Exports sales impacted due to higher logistics cost
4. Sales into Non-emissive applications continues to look robust
5. The growth in refrigerant gas will not come from R22, but other products because most of the OEMs are reducing the use of R22
Capex
1. Debottlenecking will be completed by Nov- Dec 2022 and will
will generate 65-70$ million in revenues
2. Evaluating options to setup new hydrochloric acid plant in Dahej
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. The company’s performance for the quarter was affected by headwinds in the pharmaceutical business.
But was partly mitigated due to robust performance in the Contract Research and Development Services (CRDS) segment.
2. While the Radiopharma business showed improved performance, Generics business was affected by lower volumes due to Import Alert at Roorkee plant, latest sartan impurities issue and pricing pressure in the US generics market.
1. They have had a very strong quarter - especially in CRAMS where the pipeline continues to be very strong.
2. They are seeing good interest and strong growth in the Vitamin D analogues.
3. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers.
4. They have seen a rapid rise in transportation and logistics costs. There are also price rises in Central Europe for basic utilities like electricity, gas and water.
1. Revenues stood at ₹475 Cr in Q3FY22 compared to ₹366 Cr in Q3FY21, growth of 29.4% YoY
2. EBITDA stood at 109.3 Cr translating 23% EBITDA margins
3. Sales volumes were down by 13.77% from 31,993 MT in Q3FY21 to 27,589 MT in Q3FY22. As few of the clients couldn’t procure Key Starting Materials (KSMs) to match the products.
4. Despite sluggish demand for few of the products and shut down of acetonitrile and DMF plants for debottlenecking which were completed in the month of November 2021, the revenues showed a decent growth of 44% which stood at ₹556 Cr in Q3FY22
1. Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%.
2. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments viz. anti-infectives, gastrointestinal, urological and respiratory performed well.